FENCFennec Pharmaceuticals Inc.
Price
+12%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, growing in the filings, the market undecided.
Charts
As reported to the SEC, without any scoring.
Fennec Pharmaceuticals Inc. (FENC) reported revenue of $18M in Q2 2026 (quarter ended Jun 30, 2026), up 85% from the same quarter a year earlier. That came with net income of $2.0M (11% of revenue). For the full year FY2025, revenue was $45M (−6.1% year on year) and net income −$9.7M.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 17, 2026On September 17, 2026, Fennec Pharmaceuticals Inc. (the “Company”) announced positive results from the investigator-initiated Phase 2 STS-J01 clinical study of PEDMARK® in Japan, which met its primary endpoint and demonstrated significant hearing protection without evidence of interference with cisplatin antitumor …Other event · Form 8-K
- May 22, 2026On May 21, 2026, Fennec Pharmaceuticals Inc. (the “Company”) announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as part of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting program.Other event · Form 8-K
- May 18, 2026Compensatory Arrangements of Certain Officers On May 11, 2026, the Compensation Committee of the Board of Directors of Fennec Pharmaceuticals Inc. approved grants of stock options to purchase an aggregate of 50,000 common shares to three new employees under the Company’s 2026 Equity Inducement Plan, with a grant date …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.